Dr. Suryadevara had her medical education at Osmania Medical College, her residency at the University of Nevada, School of Medicine and specialized in Oncology and Hematology with her fellowship at the University of New Mexico. She specialized in benign hematology, breast cancer and gynecologic cancer. She values building trusting relationships with her patients and considers it a privilege and solemn responsibility to be part of their advocacy team. She listens and not just hears her patients and open to negotiating goals of care.
Sutter Health Research Enterprise
2001 Dwight Way
Berkeley, CA, 94704
(510) 204-1591
suryadu@sutterhealth.org
Primary Research Interests
Related Clinical Trials
Connect
Connect® MDS/AML Disease Registry
Investigators: Rajesh Behl M.D., Oleg I. Krijanovski M.D., Ph.D., Uma Suryadevara MD
Status: Active, Recruiting
Interventional (A012103) (OptimICE-PCR)
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
Investigator: Uma Suryadevara MD
Status: Active, Recruiting
Interventional (Alliance A022102)
mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Gastroesophageal Adenocarcinoma
Investigator: Uma Suryadevara MD
Status: Active, Recruiting
INTERVENTIONAL (SWOG S2212 SCARLET)
Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer
Investigator: Uma Suryadevara MD
Status: Active, Recruiting
Locally Advanced evERA Breast Cancer
A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With The Physician's Choice of Endocrine Therapy Plus Everolimus in Particip
Investigators: Xin Li MD, Uma Suryadevara MD
Status: Active, Recruiting
Locally Advanced (Ascent-05)
A Phase III, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With The Physician's Choice o
Investigators: Nitin Rohatgi MD, Uma Suryadevara MD
Status: Active, Recruiting
Locally Advanced or Metastatic (Alliance A082002)
Testing the Addition of RT to the Usual Treatment (Immunotherapy +/- Chemotherapy) for Stage IV Non-Small Cell Lung Cancer Patients Who Are PD-L1 Negative
Investigator: Uma Suryadevara MD
Status: Active, Recruiting
Metastatic (Alliance A032001)
Testing the Addition of the Anti-cancer Drug, Cabozantinib, to the Usual Immunotherapy Trmt, Avelumab, in Pts With Metastatic Urothelial Cancer, MAIN-CAV Study
Investigator: Uma Suryadevara MD
Status: Active, Recruiting